Cytotoxicity (CC50) of some ligands and coordination compounds, measured by MTT test (nt – non toxic; dash – not tested).
| Compound | CC50, μM | ||||
|---|---|---|---|---|---|
| A549 | MCF7 | MCF10A | VA13 | HEK293T | |
| 4e | 4.11 ± 0.97 | 8.38 ± 2.26 | 3.28 ± 0.43 | 4.26 ± 0.94 | — |
| 4g | nt | 18.79 ± 5.42 | nt | 61.49 ± 3.68 | — |
| 4h | 77.26 ± 32.39 | 33.91 ± 12.97 | 10.48 ± 2.73 | 51.66 ± 5.1 | — |
| 4i | nt | nt | 3.28 ± 0.43 | 47.1 ± 5.51 | — |
| 4j | 11.59 ± 0.16 | 2.32 ± 0.48 | 7.74 ± 1.03 | 10.83 ± 2.36 | — |
| 4k | 105 ± 21.92 | 33.6 ± 2.63 | 11.45 ± 0.76 | 45.5 ± 0.31 | — |
| 5b | 3.1 ± 0.1 | 2.7 ± 0.3 | — | 2.1 ± 0.3 | 2.4 ± 0.2 |
| 5d | 2.47 ± 0.53 | 0.49 ± 0.07 | 1.71 ± 0.52 | 4.18 ± 2.58 | — |
| 5e | 1.23 ± 0.22 | 1.49 ± 0.38 | 1.2 ± 0.12 | 5.18 ± 3 | — |
| 5f | 7.9 ± 2.4 | 5.9 ± 0.7 | — | 3.9 ± 0.2 | 6.8 ± 2.7 |
| 5h | 7.4 ± 0.6 | 5 ± 0.6 | — | — | — |
| 5i | 1.74 ± 0.34 | 1.09 ± 0.02 | 0.87 ± 0.04 | 1.13 ± 0.07 | — |
| 5j | 4.8 ± 0.2 | 4.2 ± 0.5 | — | — | — |
| 5k | 6.13 ± 0.23 | 4.66 ± 3.89 | 3.63 ± 1.95 | 2.04 ± 1.23 | — |
| 6e | 0.7 ± 0.1 | 1.8 ± 0.2 | — | 0.5 ± 0 | 1.6 ± 0.2 |
| 6f | 1.8 ± 0.1 | 1.9 ± 0.1 | — | 1.6 ± 0.1 | 2.4 ± 0.1 |
| 6i | 9.2 ± 0.5 | 6.9 ± 0.3 | — | 5.2 ± 0.3 | 7.4 ± 3.2 |
| 6k | 9.3 ± 0.5 | 8.4 ± 0.4 | — | 6 ± 0.4 | 6.8 ± 1.0 |
| Cisplatin, μM | >30 | a14 ± 2.3 (48 h) | a11 ± 3 (48 h) | 2.9 ± 0.3 | 12.4 ± 3.9 |
| a9 ± 1.7 (72 h) | a7 ± 0.8 (72 h) | ||||
| Doxorubicin, nM | 47.9 ± 7.9 | 55.4 ± 11.8 | — | 159.9 ± 27.4 | 11.5 ± 3.2 |
a
Ref. 50.